Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
about
A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokineticsImatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.Reduced exposure of imatinib after coadministration with acetaminophen in miceCopy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia.Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.
P2860
Q24602122-046A735B-92D4-443C-9542-768E3DF9B956Q33557847-47535A6D-3EFA-4838-BF77-1427F49A56DEQ34106390-D07863E0-478E-4ABE-9FA1-6B6B1BEE7770Q34389029-ADA15B27-BC9F-4000-B4C9-25775482B0C5Q34525644-FF668596-467B-4ECE-BD28-77EFC7D7D759Q34580581-C6BCFBBA-A3EF-41C6-9B37-27F932A3F4D8Q35023711-A747EBE4-A473-4F91-B08C-6463370F777EQ35115436-05A48EF3-78DF-403F-A0A3-CE8B0FFAEE03Q35846126-DD8B3309-7B8F-468C-9B88-4A8640CF3BD7Q36328417-8CD67E13-5AB5-48B3-AA36-EB7D1AD8E229Q36365500-F0B3934A-7A63-44E4-8A98-4D42B0C946B7Q37981002-4F635B08-2954-4E80-8C73-859BA1525010Q38099040-9C77D0A0-5B98-4050-8E78-F2D55D48C2ECQ39239760-734857DF-4DC4-4789-BB6A-F355BC8633F2Q40729511-A400F4EB-20BD-4E56-B9C3-1D10D1E7CD00Q41144255-0E5FAF48-E735-4CD1-A369-B73E272BD9CDQ42283688-7544DCC5-DFE9-4933-B014-99CC68BF6AE6Q42793905-52A6B3E6-CC91-49A2-A977-93FE3218AE91Q43841175-6FF8BE74-86E0-430D-BC6D-03815DDEB5EBQ45160680-715936A9-51B1-4EF5-99BF-473D162B98F1Q53257546-83840AAE-63E7-439E-B885-688605B7994B
P2860
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@ast
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@en
type
label
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@ast
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@en
prefLabel
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@ast
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@en
P2093
P2860
P1476
Effects of imatinib (Glivec) o ...... chronic myelogenous leukaemia.
@en
P2093
Catherine Dutreix
Elisabeth Leroy
Gilles-Jacques Riviere
Horst Schran
Ophelia Q P Yin
Venkat Sethuraman
Yanfeng Wang
Zhi-Xiang Shen
P2860
P304
P356
10.1111/J.1365-2125.2008.03150.X
P407
P577
2008-04-01T00:00:00Z